Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Daiichi Sankyo
US Army
Moodys
Accenture
Merck
US Department of Justice
Cipla
Cerilliant

Generated: April 26, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,723,390

« Back to Dashboard

Which drugs does patent 7,723,390 protect, and when does it expire?

Patent 7,723,390 protects TIROSINT and is included in one NDA.

This patent has eight patent family members in eight countries.
Summary for Patent: 7,723,390
Title:Pharmaceutical formulations for thyroid hormones
Abstract:The present invention provides for pharmaceutical formulations based on thyroid hormones enabling a safe and stable oral administration in the framework of the strict therapeutic index prescribed in case of thyroid disorders.
Inventor(s): Garavani; Alberto (Ponte Capriasca, CH), Marchiorri; Maurizio (Valbrona, IT), Di Martino; Alessandro (Milan, IT), Mateo Echanagorria; Angel (Milan, IT)
Assignee: Altergon S.A. (Lugano, CH)
Application Number:10/188,467
Patent Claim Types:
see list of patent claims
Composition; Dosage form; Formulation;

Drugs Protected by US Patent 7,723,390

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Institut Biochimique TIROSINT levothyroxine sodium CAPSULE;ORAL 021924-013 Aug 1, 2007 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Institut Biochimique TIROSINT levothyroxine sodium CAPSULE;ORAL 021924-002 Oct 13, 2006 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Institut Biochimique TIROSINT levothyroxine sodium CAPSULE;ORAL 021924-003 Oct 13, 2006 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Institut Biochimique TIROSINT levothyroxine sodium CAPSULE;ORAL 021924-004 Oct 13, 2006 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,723,390

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
ItalyMI2001A1401Jul 02, 2001

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Harvard Business School
Fuji
Queensland Health
AstraZeneca
US Department of Justice
QuintilesIMS
Deloitte
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.